Dec 14, 2022 / 02:00PM GMT
Unidentified Company Representative -
Welcome, everybody, to the 2022 Y-mAbs R&D Day. We will have the presentations by management over the next 1.5 hours, and we're very excited to share their plans. Please note the disclaimer here and forward-looking statements, and you can read them and check the website and the SEC filings.
At this point, I'd like to invite Thomas Gad, Founder, Interim CEO, Head of Business Development and Strategy and overall inspirational guy [to move into the slides].
Thomas Gad - Y-mAbs Therapeutics, Inc. - Founder, Interim CEO, President, Head of Business Development & Strategy and Director
Thanks, [Sanjay]. Thanks. Good morning, everyone, and thank you for being here today and spending time with Y-mAbs. We are in an exciting period of time, a little bit overshadowed by our ODAC vote, but we will manage through that as well. So I'll start with a short update, company update. Then we'll hear from Steen Lisby, our Chief Scientific Officer, who will focus on our exciting SADA development. And after that, we will hear from Vignesh,
Y-mAbs Therapeutics Inc To Host Annual Research and Development Day Transcript
Dec 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers